Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Sionna Therapeutics is presenting previously disclosed post hoc PreciSION CF analyses and new preclinical data at the 2026 North American Cystic Fibrosis Conference in Atlanta. The original PreciSION trial of SION-719 added to Trikafta missed its key activity endpoint, but post hoc analyses excluding three non-adherent participants showed a mean placebo-adjusted sweat chloride reduction of 8.6 mmol/L, with identified drug-drug interactions complicating interpretation.
Key figures
- Drug Name
- SION-451 + SION-2222 (and SION-719)
- Phase Of Trial
- Phase 2a
- Trial duration
- 28-day open-label
- Expected trial start
- Q1 2027
- Placebo adjusted sweat chloride reduction
- 8.6 mmol/L
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.